Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026
177Lu-PSMA-617 (Pluvicto) Combo With Sipulecel-T in Phase 1 Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxCity of Hope Medical Center, in collaboration with the National Cancer Institute, is initiating a randomized phase 1 study in metastatic castration‑resistant prostate cancer (mCRPC) that compares lutetium Lu 177 vipivotide tetraxetan (177Lu‑PSMA‑617 or Pluvicto) alone versus the same radioligand combined with sipuleucel‑T, with the primary goal of quantifying the induced anti‑tumor immune response alongside […]
News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule
/in Delivery, Preclinical Research/by MaxA novel dual payload peptide drug conjugate technology, known as the pre|CISION® platform, represents an advance in oncology by delivering two complementary anticancer therapies from a single molecule. This approach leverages the fibroblast activation protein (FAP), which is selectively present in the tumor microenvironment, especially in advanced prostate cancer such as castration-resistant prostate cancer (CRPC). […]
Helicon Degraders Show a New Path in Prostate Cancer Therapy
/in Preclinical Research/by MaxIn one of the most compelling advances for prostate cancer biology in recent years, a novel peptide-based degrader has achieved potent, selective elimination of the transcription factor ERG, an oncogenic driver long considered unreachable by medicinal chemistry. The discovery has upended conventional views on druggability in TMPRSS2–ERG fusion–positive prostate cancers, which comprise nearly half of […]
UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA first-in-human clinical trial conducted at The University of Texas MD Anderson Cancer Center has revealed encouraging early results for HLD-0915, a new oral therapy designed for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, indicate that HLD-0915 is well tolerated and […]
Final OS Data from EMBARK Phase 3 Trial: Enzalutamide With ADT for Men at Risk of BRPC
/in Clinical Trial, Non-Metastatic, Phase 3/by MaxData from the phase 3 EMBARK trial, combining enzalutamide with standard hormone therapy, recently published in The New England Journal of Medicine and presented at the 2025 European Society for Medical Oncology (ESMO) Congress, reveal that this combination reduces the risk of death by more than 40% over eight years compared to hormone therapy alone. […]
UPDATE About ENV-105: Promising Phase 2 Interim Results for mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxThe investigational drug ENV-105 (carutoximab), a first-in-class CD105 antagonist, has shown promising interim efficacy results in a Phase 2 clinical trial involving patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after standard hormone therapies. This ongoing trial evaluated the combination of ENV-105 with apalutamide, a commonly used hormone therapy. Among patients treated, 86% […]
KLS-3021: a Promising Oncolytic Virus for Prostate Cancer
/in Oncolytic, Preclinical Research/by MaxKLS-3021 is a novel oncolytic virus therapy developed for the treatment of prostate cancer. It employs a recombinant vaccinia virus engineered to selectively infect and destroy cancer cells while activating the immune system to target tumors more effectively. The virus carries three therapeutic genes: PH-20, which degrades the extracellular matrix to facilitate viral spread and […]
ESMO Congress 2025 Confirms the Role of AI in Cancer Treatment
/in Artificial Intelligence/by MaxAt the ESMO Congress 2025 held in Berlin, artificial intelligence demonstrated a pivotal role in reshaping cancer treatment through novel biomarker applications. Studies presented at this event showed how AI models analyzing pathology images, imaging data, and genomic profiles can improve predictions of patient responses to therapies. For example, in metastatic colorectal cancer, AI identified […]